276 related articles for article (PubMed ID: 28410529)
1. IFNγ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells.
Shao S; Risch E; Burner D; Lu L; Minev B; Ma W
Int Immunopharmacol; 2017 Jun; 47():159-165. PubMed ID: 28410529
[TBL] [Abstract][Full Text] [Related]
2. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.
Xiaobing J; Xiaoling L; Ruen L; Fangcheng Z; Hongyang Z
Cancer Biother Radiopharm; 2007 Dec; 22(6):826-35. PubMed ID: 18158774
[TBL] [Abstract][Full Text] [Related]
3. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
[TBL] [Abstract][Full Text] [Related]
4. Improvement of the cytotoxic T lymphocyte response against hepatocellular carcinoma by transduction of cancer cells with an adeno-associated virus carrying the interferon-γ gene.
Zhou J; Ma P; Li J; Cui X; Song W
Mol Med Rep; 2016 Apr; 13(4):3197-205. PubMed ID: 26936017
[TBL] [Abstract][Full Text] [Related]
5. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
[TBL] [Abstract][Full Text] [Related]
6. Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells.
Liu X; Li J; Liu Y; Ding J; Tong Z; Liu Y; Zhou Y; Liu Y
Cell Immunol; 2016 Feb; 300():46-53. PubMed ID: 26702740
[TBL] [Abstract][Full Text] [Related]
7. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
8. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.
Mimura K; Ando T; Poschke I; Mougiakakos D; Johansson CC; Ichikawa J; Okita R; Nishimura MI; Handke D; Krug N; Choudhury A; Seliger B; Kiessling R
Int J Cancer; 2011 Jan; 128(2):390-401. PubMed ID: 20715101
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
[TBL] [Abstract][Full Text] [Related]
11. Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.
Wu L; Zhang H; Jiang Y; Gallo RC; Cheng H
Proc Natl Acad Sci U S A; 2018 May; 115(19):E4453-E4462. PubMed ID: 29674449
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
13. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
14. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
15. Use of dentritic cells pulsed with HLA-A2-restricted MAGE-A1 peptide to generate cytotoxic T lymphocytes against malignant glioma.
Shi H; Jiang X; Fu P; Zhou Y; Lu X
J Huazhong Univ Sci Technolog Med Sci; 2010 Oct; 30(5):678-82. PubMed ID: 21063856
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
[TBL] [Abstract][Full Text] [Related]
17. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
18. Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.
Li H; Shao S; Cai J; Burner D; Lu L; Chen Q; Minev B; Ma W
Immunology; 2017 Nov; 152(3):462-471. PubMed ID: 28664991
[TBL] [Abstract][Full Text] [Related]
19. Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL Cytotoxicity Using a Novel Identified HLA-A2-restricted MAGE-A11 Peptide.
Zhang J; Sang M; Gu L; Liu F; Li W; Yin D; Wu Y; Liu S; Huang W; Shan B
J Immunother; 2017; 40(6):211-220. PubMed ID: 28486273
[TBL] [Abstract][Full Text] [Related]
20. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
